HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.

We examined the effects of the calcium channel blockers nitrendipine, diltiazem, verapamil, bepridil, and mibefradil on the cloned HERG and KvLQT1/IsK K+ channels. These channels generate the rapid and slow components of the cardiac delayed rectifier K+ current, and mutations can affect them, which leads to long QT syndromes. When expressed in transfected COS cells, HERG is blocked in a concentration-dependent manner by bepridil (EC50 = 0.55 microM), verapamil (EC50 = 0.83 microM), and mibefradil (EC50 = 1.43 microM), whereas nitrendipine and diltiazem have negligible effects. Steady state activation and inactivation parameters are shifted to more negative values in the presence of the blockers. Similarly, KvLQT1/IsK is inhibited by bepridil (EC50 = 10.0 microM) and mibefradil (EC50 = 11.8 microM), while being insensitive to nitrendipine, diltiazem, or verapamil. These results demonstrate that both cloned K+ channels HERG and KvLQT1/IsK, which represent together the cardiac delayed rectifier K+ current, are sensitive targets to calcium channel blockers. This work may help in understanding the mechanisms of action of verapamil in certain ventricular tachycardia, as well as some of the deleterious adverse cardiac events associated with bepridil.

[1]  A. Brown,et al.  Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.

[2]  S. Grissmer,et al.  Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3. , 1996, Molecular pharmacology.

[3]  B. Massie.  Mibefradil: a selective T-type calcium antagonist. , 1997, The American journal of cardiology.

[4]  Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and Lidoflazine , 1990, Pacing and clinical electrophysiology : PACE.

[5]  B. Fermini,et al.  Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them , 1992 .

[6]  A. Brown,et al.  Bepridil block of cardiac calcium and sodium channels. , 1986, The Journal of pharmacology and experimental therapeutics.

[7]  B. Fermini,et al.  IK of rabbit ventricle is composed of two currents: evidence for IKs. , 1996, The American journal of physiology.

[8]  D. Roden,et al.  Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. , 1991, Circulation research.

[9]  J. Pancrazio,et al.  Verapamil-induced blockade of voltage-activated K+ current in small-cell lung cancer cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[10]  Nie Fe.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[11]  B. Singh,et al.  When is QT prolongation antiarrhythmic and when is it proarrhythmic? , 1989, The American journal of cardiology.

[12]  M. Lazdunski,et al.  Properties of KvLQT1 K+ channel mutations in Romano–Ward and Jervell and Lange‐Nielsen inherited cardiac arrhythmias , 1997, The EMBO journal.

[13]  G. Klein,et al.  Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. , 1983, American heart journal.

[14]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[15]  D. Escande,et al.  KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl- chromane. , 1997, Molecular pharmacology.

[16]  B. Attali.  A new wave for heart rhythms , 1996, Nature.

[17]  R. Brooks,et al.  Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent , 1997 .

[18]  G. Yellen,et al.  Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. , 1994, BioTechniques.

[19]  S. Ertel,et al.  Discovery and main pharmacological properties of mibefradil (Ro 40‐5967), the first selective T‐type calcium channel blocker , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[20]  G. Ducloux,et al.  Nine cases of torsade de pointes with bepridil administration. , 1986, American heart journal.

[21]  M. Gheorghiade,et al.  Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. , 1997, Progress in cardiovascular diseases.

[22]  Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. , 1991, European heart journal.

[23]  P. Walter,et al.  Anatomy of atrioventricular nodal reentry investigated by intracardiac echocardiography. , 1997, The American journal of cardiology.

[24]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[25]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[26]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[27]  T. DeCoursey.  Mechanism of K+ channel block by verapamil and related compounds in rat alveolar epithelial cells , 1995, The Journal of general physiology.

[28]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[29]  J. Hume.  Comparative interactions of organic Ca++ channel antagonists with myocardial Ca++ and K+ channels. , 1985, The Journal of pharmacology and experimental therapeutics.

[30]  S Nattel,et al.  Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. , 1996, Circulation research.

[31]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[32]  R. Sung,et al.  Spectrum off electrophysiologic and electropharmacologic characteristics of verapamil-sensitive ventricular tachycardia in patients without structural heart disease , 1996 .

[33]  M. Sanguinetti,et al.  Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.

[34]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[35]  A. Camm,et al.  Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. , 1993, American heart journal.

[36]  G. Billman,et al.  The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. , 1996, The Journal of pharmacology and experimental therapeutics.

[37]  R. Sung,et al.  Cellular and Clinical Electrophysiology of Verapamil‐Sensitive Ventricular Tachycardias , 1992 .

[38]  Jacques Barhanin,et al.  KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current , 1996, Nature.